Novel cardiovascular magnetic resonance imaging biomarkers to track response to treatment including Sotatercept in a patient with idiopathic pulmonary arterial hypertension: a case report.
4 affiliations
- 1Clinical Physiology, Department of Clinical Sciences Lund, Lund University, Entrégatan 7, 222 42 Lund, Sweden.
- 2Department of Clinical Physiology, Skåne University Hospital, Entrégatan 7, 222 42 Lund, Sweden.
- 3Cardiology, Department of Clinical Sciences Lund, Lund University, Skånes universitetssjukhus, EA-blocket, 221 85 Lund, Sweden.
- 4Haemodynamic Lab, Section for Heart Failure and Valvular Disease, Skåne University Hospital, Entrégatan 7, 222 43 Lund, Sweden.
Abstract
Pulmonary arterial hypertension (PAH) causes progressive right ventricular (RV) pressure overload and left ventricular (LV) underfilling. Sotatercept is an activin-signal inhibitor, approved by FDA in 2024 and EMA in 2025, as an add-on treatment in adult patients with PAH. Cardiovascular magnetic resonance (CMR)-derived atrioventricular plane displacement (AVPD) and left ventricular pressure-volume (PV) loops may represent non-invasive markers of treatment response, particularly important as novel therapies addressing remodelling emerge. A 30-year-old woman was diagnosed with idiopathic PAH, after presenting with dyspnoea and peripheral oedema. Baseline CMR showed severe RV dilation, reduced RV ejection fraction, and low indexed LV stroke volume, with reduced bilateral AVPD and markedly impaired LV PV loop indices, with low stroke work, low mean external power, and high ventriculo-arterial coupling. Initial dual PAH therapy, with an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor initially improved symptoms, pulmonary vascular resistance, as well as AVPD and PV loop derived indices, whereas conventional CMR indices showed only minimal change. One year later, despite triple therapy, including prostacyclin analogue, the patient deteriorated clinically and CMR showed worsening of AVPD and PV loop indices. Treatment escalation with Sotatercept immediately improved clinical status, haemodynamic, AVPD, and PV loop indices despite persistent RV remodelling. Serial CMR-derived AVPD and LV PV loops may provide clinically useful additional information during longitudinal follow-up of PAH patients, especially in those approaching maximal available medical therapies. In the present case, both AVPD and LV PV loops reflected treatment response, and showed significant improvement after initiation of Sotatercept.
Related
- Sotatercept-related peripheral microvascular alterations in systemic sclerosis–associated pulmonary arterial hypertension: insights from nailfold capillaroscopy
- Salvage Use of Sotatercept for Potts Shunt in Refractory Pulmonary Hypertension.
- Sotatercept as a Treatment for Pulmonary Hypertension Associated With Connective Tissue Disease and ILD.
- Case Report: Upfront sotatercept-based triple therapy in high-risk systemic sclerosis-associated pulmonary arterial hypertension
- Regional Perivascular Space Burden in Pediatric Idiopathic Intracranial Hypertension: A Case–Control MRI Study
BibTeX
@article{castiglione2026novel,
title = {{Novel cardiovascular magnetic resonance imaging biomarkers to track response to treatment including Sotatercept in a patient with idiopathic pulmonary arterial hypertension: a case report.}},
author = {Alessandro Castiglione and Barbro Kjellström and Göran Rådegran and Ellen Ostenfeld},
journal = {European heart journal. Case reports},
year = {2026},
month = oct,
doi = {10.1093/ehjcr/ytag763},
url = {https://europepmc.org/article/MED/42953734},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Novel cardiovascular magnetic resonance imaging biomarkers to track response to treatment including Sotatercept in a patient with idiopathic pulmonary arterial hypertension: a case report.
AU - Alessandro Castiglione
AU - Barbro Kjellström
AU - Göran Rådegran
AU - Ellen Ostenfeld
PY - 2026
DA - 2026/10/26
JO - European heart journal. Case reports
DO - 10.1093/ehjcr/ytag763
UR - https://europepmc.org/article/MED/42953734
AB - Pulmonary arterial hypertension (PAH) causes progressive right ventricular (RV) pressure overload and left ventricular (LV) underfilling. Sotatercept is an activin-signal inhibitor, approved by FDA in 2024 and EMA in 2025, as an add-on treatment in adult patients with PAH. Cardiovascular magnetic resonance (CMR)-derived atrioventricular plane displacement (AVPD) and left ventricular pressure-volume (PV) loops may represent non-invasive markers of treatment response, particularly important as novel therapies addressing remodelling emerge. A 30-year-old woman was diagnosed with idiopathic PAH, after presenting with dyspnoea and peripheral oedema. Baseline CMR showed severe RV dilation, reduced RV ejection fraction, and low indexed LV stroke volume, with reduced bilateral AVPD and markedly impaired LV PV loop indices, with low stroke work, low mean external power, and high ventriculo-arterial coupling. Initial dual PAH therapy, with an endothelin receptor antagonist and a phosphodiesterase-5 inhibitor initially improved symptoms, pulmonary vascular resistance, as well as AVPD and PV loop derived indices, whereas conventional CMR indices showed only minimal change. One year later, despite triple therapy, including prostacyclin analogue, the patient deteriorated clinically and CMR showed worsening of AVPD and PV loop indices. Treatment escalation with Sotatercept immediately improved clinical status, haemodynamic, AVPD, and PV loop indices despite persistent RV remodelling. Serial CMR-derived AVPD and LV PV loops may provide clinically useful additional information during longitudinal follow-up of PAH patients, especially in those approaching maximal available medical therapies. In the present case, both AVPD and LV PV loops reflected treatment response, and showed significant improvement after initiation of Sotatercept.
SN - 2514-2119
ER -